Litcius/Paper detail

Iron stored in ferritin is chemically reduced in the presence of aggregating Aβ(1-42)

James Everett, Jake Brooks, Frederik Lermyte, Peter B. O’Connor, Peter J. Sadler, Jon Dobson, Joanna F. Collingwood, Neil D. Telling

2020Scientific Reports54 citationsDOIOpen Access PDF

Abstract

Atypical low-oxidation-state iron phases in Alzheimer's disease (AD) pathology are implicated in disease pathogenesis, as they may promote elevated redox activity and convey toxicity. However, the origin of low-oxidation-state iron and the pathways responsible for its formation and evolution remain unresolved. Here we investigate the interaction of the AD peptide β-amyloid (Aβ) with the iron storage protein ferritin, to establish whether interactions between these two species are a potential source of low-oxidation-state iron in AD. Using X-ray spectromicroscopy and electron microscopy we found that the co-aggregation of Aβ and ferritin resulted in the conversion of ferritin's inert ferric core into more reactive low-oxidation-states. Such findings strongly implicate Aβ in the altered iron handling and increased oxidative stress observed in AD pathogenesis. These amyloid-associated iron phases have biomarker potential to assist with disease diagnosis and staging, and may act as targets for therapies designed to lower oxidative stress in AD tissue.

Topics & Concepts

FerritinOxidative stressFerricPathogenesisBiomarkerChemistryAmyloid (mycology)RedoxFERRIC IRONBiophysicsBiochemistryCell biologyBiologyMedicinePathologyInorganic chemistryOrganic chemistryFerrousAlzheimer's disease research and treatmentsTrace Elements in HealthIron Metabolism and Disorders
Iron stored in ferritin is chemically reduced in the presence of aggregating Aβ(1-42) | Litcius